Mark Sculpher

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

Gillian D Sanders, Peter J. Neumann, Anirban Basu et al. · JAMA · 2016 · 3K citations · Full text

Pharmacy, Health Administration, Health Policy +17

Representing uncertainty: the role of cost‐effectiveness acceptability curves

Elisabeth Fenwick, Karl Claxton, Mark Sculpher · Health Economics · 2001 · 1.1K citations

Pharmacy, Pharmacoeconomics, Decision Analysis +14

Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility

Andrea Manca, Neil Hawkins, Mark Sculpher · Health Economics · 2004 · 1.1K citations

Pharmacy, Biostatistics, Pharmacoeconomics +16

Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research

Beth Woods, Paul Revill, Mark Sculpher et al. · Value in Health · 2016 · 925 citations · Full text

Pharmacy, Economics, Pharmacoeconomics +16

Model Parameter Estimation and Uncertainty Analysis

Andrew Briggs, Milton C. Weinstein, Elisabeth Fenwick et al. · Medical Decision Making · 2012 · 886 citations · Full text

Computing, Decision Sciences, Health Policy +17